Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by analysts at BMO Capital Markets in a research report issued on Friday. They currently have a $82.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ target price points to a potential upside of 0.97% from the stock’s current price.

GILD has been the subject of several other reports. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.64.

Gilead Sciences (NASDAQ:GILD) traded down 0.47% during mid-day trading on Friday, reaching $81.21. The company’s stock had a trading volume of 9,078,587 shares. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27. The firm has a market cap of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14. The company has a 50-day moving average price of $82.70 and a 200-day moving average price of $72.55.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.08 EPS. On average, equities research analysts expect that Gilead Sciences will post $8.74 earnings per share for the current year.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/20/bmo-capital-markets-reaffirms-hold-rating-for-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock valued at $36,338,919 in the last three months. Insiders own 1.30% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the last quarter. Paradigm Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after acquiring an additional 26 shares during the last quarter. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the last quarter. First Heartland Consultants Inc. lifted its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC lifted its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 41 shares during the last quarter. 73.97% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.